MINUTES
About Minutes
Back to latest

EconomyAkeso shares plunge after FDA setback for cancer drug ivonescimab

Shares in Hong Kong-listed Akeso fell as much as 31.8 per cent on Monday morning after the FDA rejected its application for cancer drug ivonescimab, prompting investor concerns about the company’s near-term commercial outlook.

AkesoivonescimabFDAdrug approval

SSouth China Morning Post★★☆☆☆2026-11-16 05:00Original

Akeso shares plunge after FDA setback for cancer drug ivonescimab
Akeso shares plunge after FDA setback for cancer drug ivonescimabEconomy